

# Navigating Long-Term Care for Cold Agglutinin Disease

Sustaining Alignment as Disease and Life Evolve




Even after a clear diagnosis, patients live with CAD for years. Disease activity fluctuates, therapies change, and risks accumulate. Expert care depends on knowing how to adjust course without overreacting or drifting.

*“Cold agglutinin disease is rarely a one-decision illness.”*

— Berentsen S. *Hematology Am Soc Hematol Educ Program*. 2016

# CAD is a chronic disease with a variable, fluctuating tempo.

Most patients follow a relapsing course rather than a linear trajectory.



## Typical Patterns:

- Stable periods interrupted by exacerbations.
- Symptoms fluctuating independently of hemoglobin levels.
- Partial rather than complete responses to treatment.




## Biological Nuance:



The clonal B-cell disorder and the hemolytic process may evolve on different timelines. Clone progression can occur despite stable anemia, while hemolysis may worsen without clonal transformation. Long-term monitoring must track both processes independently.

# The Goal: Sustaining alignment, not forcing normalization.



**Long-term management requires comfort with imperfection.**

Expert care accepts that "stability" means predictable, acceptable disease impact within the patient's lived reality, rather than forcing laboratory values to normal range at the cost of high treatment burden.

# Laboratory values describe hemolysis. They do not describe life.


## The Chart



Hemoglobin: 9.2 g/dL



Bilirubin: Elevated



LDH: 1.5x ULN



## The Lived Reality



Chronic Fatigue



Cold-induced circulatory symptoms



Functional limitations

Fear of winter



- **Evidence:** Quality-of-life studies confirm that patient-reported burden often diverges from laboratory indices (Joly F et al. JMIR Formative Research. 2022).
- **Monitoring Mandate:** Longitudinal monitoring must integrate hemoglobin trends, transfusion exposure, and functional limitations alongside standard hemolysis markers.


# Stability does not always mean 'no treatment'.



- **Clinical Implication:** These states are not interchangeable. Stability maintained by suppression carries different monitoring implications than stability reflecting intrinsic disease tempo. Failure to distinguish them leads to therapeutic errors. (Source: Berentsen S. Blood. 2021)

# Monitoring cadence should match disease behavior.

There is no universal follow-up interval.



**Key Factor:** Cadence must reflect not just disease activity, but comorbid risk and the reliability of the patient's own reporting.

# Surveillance should follow mechanism.

Monitor based on how the treatment works.

## Complement-Directed Therapy

Monitor for hemolysis control, infection risk (encapsulated bacteria), and vaccination status.

## Clone-Directed Therapy

Monitor for cytopenias, general immune suppression, delayed responses, and relapse.

## Supportive Strategies

Monitor disease trajectory and cold triggers.

**Takeaway:** Monitor what could change management, not simply what can be measured. Therapy-specific monitoring reflects therapy-specific risk. (Berentsen S. *Frontiers in Immunology*. 2020).

# Avoiding the twin errors: Therapeutic Inertia vs. Therapeutic Overreach.



1. Has the disease meaningfully changed?

2. Has the patient experience changed?

3. Has the risk–benefit balance shifted?

# Expert care plans for relapse. It does not wait for it.

## Anticipatory Planning

- Educate patients on warning signs
- Define thresholds for reassessment
- Document prior effective interventions
- Clarify escalation strategies in advance

## Warning Signs



Dark  
urine



New  
fatigue



Worsening  
cold sensitivity




**Insight:** Relapse is common and expected, not exceptional.  
Preparation reduces crisis decision-making.




# Reassessment is a longitudinal skill, not an admission of failure.

A plan that was appropriate two years ago can become inappropriate without ever having been wrong. Effective reassessment is routine maintenance.



Reassessment ensures the therapy continues to serve the patient as they age and the disease evolves. >>

# The patient's life changes, even if the disease does not.



**Disease burden and treatment tolerance may shift independently of hemolysis markers.**



Long-term care succeeds when it adapts to the person, not just the pathology. (Pham HP et al. *Am J Hematol.* 2022).



# Documentation is anticipatory planning made durable.

Essential for shared care across multiple settings.



## MEDICAL RECORD SUMMARY / SHARED CARE PLAN

- Confirmed diagnosis & dominant mechanism
- Prior therapies & specific responses
- Known triggers (environmental/thermal)
- Monitoring parameters & action thresholds
- Patient goals
- Perioperative precautions




Documentation prevents knowledge loss when patients move between clinicians.

# The Pillars of Long-Term Success

Long-term management in cold agglutinin disease is not about maintaining control at all costs. It is about maintaining **alignment** between biology, therapy, and patient priorities.

**Success is measured not by the absence of fluctuation, but by the patient's ability to live predictably, safely, and well alongside a disease disappears yet can be managed.**



# Key Literature & References



Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016.

Berentsen S et al. Cold agglutinin disease revisited: a multinational observational study of 232 patients. Blood. 2020.

Jäger U et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults. Blood Reviews. 2020.

Swiecicki PL et al. Cold agglutinin disease. Blood. 2013.

Joly F et al. The burden of cold agglutinin disease on patients' daily life. JMIR Formative Research. 2022.

Hill QA et al. The diagnosis and management of primary autoimmune haemolytic anaemia. British Journal of Haematology. 2016.

Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Frontiers in Immunology. 2020.

Pham HP et al. An observational analysis of disease burden in patients with cold agglutinin disease. American Journal of Hematology. 2022.

